← Back to Screener
BioNTech SE American Depositary Share (BNTX)
Price$105.19
Favorite Metrics
Price vs S&P 500 (26W)-7.90%
Price vs S&P 500 (4W)5.80%
Market Capitalization$30.47B
All Metrics
P/CF (Annual)48.22x
Book Value / Share (Quarterly)$90.10
P/TBV (Annual)1.11x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-45.07%
Cash Flow / Share (Quarterly)$-1.37
Payout Ratio (TTM)17.60%
Price vs S&P 500 (YTD)3.97%
Gross Margin (TTM)84.21%
Net Profit Margin (TTM)-13.75%
EPS (TTM)$-5.54
10-Day Avg Trading Volume0.78M
EPS Excl Extra (TTM)$-5.54
Revenue Growth (5Y)42.88%
EPS (Annual)$-5.54
Dividend / Share (Annual)$0.00
ROI (Annual)-5.83%
Gross Margin (Annual)84.37%
Net Profit Margin (5Y Avg)13.87%
Cash / Share (Quarterly)$69.73
Revenue Growth QoQ (YoY)-23.75%
ROA (Last FY)-5.17%
Revenue Growth TTM (YoY)-11.81%
EBITD / Share (TTM)$-5.08
ROE (5Y Avg)25.77%
Operating Margin (TTM)-15.26%
Cash Flow / Share (Annual)$-1.37
P/B Ratio1.14x
P/B Ratio (Quarterly)1.01x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)6.01x
Net Interest Coverage (TTM)-1.43x
ROA (TTM)-5.28%
EV / EBITDA (TTM)14.65x
EPS Incl Extra (Annual)$-5.54
Current Ratio (Annual)7.54x
Quick Ratio (Quarterly)7.49x
3-Month Avg Trading Volume1.14M
52-Week Price Return4.75%
EV / Free Cash Flow (Annual)0.88x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$82.57
P/S Ratio (Annual)7.66x
Asset Turnover (Annual)0.13x
52-Week High$124.00
Operating Margin (5Y Avg)14.98%
EPS Excl Extra (Annual)$-5.54
CapEx CAGR (5Y)54.53%
Tangible BV CAGR (5Y)69.43%
26-Week Price Return0.84%
Quick Ratio (Annual)7.49x
13-Week Price Return-5.68%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)7.54x
Enterprise Value$17,175.228
Revenue / Share Growth (5Y)44.19%
Asset Turnover (TTM)0.11x
Book Value / Share Growth (5Y)68.27%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.28x
Pretax Margin (Annual)-36.61%
Cash / Share (Annual)$69.73
3-Month Return Std Dev57.24%
Gross Margin (5Y Avg)84.18%
Net Income / Employee (TTM)$-0
ROE (Last FY)-5.91%
Net Interest Coverage (Annual)12.06x
EPS Basic Excl Extra (Annual)$-5.54
P/FCF (TTM)19.89x
Receivables Turnover (TTM)2.02x
EV / Free Cash Flow (TTM)2.67x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-5.54
Receivables Turnover (Annual)2.39x
ROI (TTM)-5.96%
P/S Ratio (TTM)9.06x
Pretax Margin (5Y Avg)24.79%
Revenue / Share (Annual)$13.99
Tangible BV / Share (Annual)$82.57
Price vs S&P 500 (52W)-30.34%
Year-to-Date Return8.11%
5-Day Price Return6.43%
EPS Normalized (Annual)$-5.54
ROA (5Y Avg)20.29%
Net Profit Margin (Annual)-39.59%
Month-to-Date Return15.80%
Cash Flow / Share (TTM)$15.32
EBITD / Share (Annual)$-5.06
Operating Margin (Annual)-48.97%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)48.22x
ROI (5Y Avg)25.26%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-5.54
P/TBV (Quarterly)1.11x
Payout Ratio (Annual)5.13%
P/B Ratio (Annual)1.01x
Inventory Turnover (TTM)2.43x
Pretax Margin (TTM)-8.35%
Book Value / Share (Annual)$90.10
Price vs S&P 500 (13W)-8.55%
Beta1.40x
P/FCF (Annual)4.71x
Revenue / Share (TTM)$11.71
ROE (TTM)-6.05%
52-Week Low$79.52
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
HALOHalozyme Therapeutics, Inc. | 5.90x | 37.55% | 83.62% | 22.89% | $69.57 |
About
BioNTech is a German biotechnology company developing mRNA-based cancer immunotherapies and vaccines for infectious diseases. Its oncology pipeline includes multiple therapeutic modalities such as mRNA drugs, cell therapies, bispecific antibodies, and antibody-drug conjugates. The company's first commercialized product is Comirnaty, a COVID-19 vaccine developed in partnership with Pfizer.